Navigation Links
G1 Therapeutics to Present at Southeast BIO Investor & Partnering Forum
Date:11/1/2013

CHAPEL HILL, N.C., Nov. 1, 2013 /PRNewswire/ -- G1 Therapeutics, Inc. today announced that it has been selected as a MAIN/Stage presenter at the 2013 Southeast BIO Investor & Partnering Forum to be held November 6-7 at the Jefferson Hotel in Richmond, Virginia. Christy Shaffer, Ph.D., Executive Chair of G1's Board of Directors, will present to the audience of potential investors and partners on the afternoon of November 6. Jay Strum, Ph.D., President of G1, will also be in attendance. 

The annual conference sponsored by Southeast BIO (SEBIO), the regional nonprofit organization dedicated to fostering the growth of the Southeast's life sciences industry, will showcase innovative drug therapies, advanced medical devices, diagnostics and other cutting-edge healthcare technologies from throughout the Southeast. MAIN/Stage presenting companies have generally completed at least one round of institutional financing and were chosen by a selection committee of regional and national venture capitalists based on criteria including technology, market potential and company management.

G1's lead clinical candidate is a proprietary, potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been evaluated in a number of pre-clinical studies for the potential treatment of chemotherapy-induced myelosuppression. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials. Based on a recent pre-IND meeting with the U.S. Food & Drug Administration, the company expects to file its IND by summer 2014 and initiate clinical testing before the end of 2014. 

About G1 Therapeutics, Inc.

G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be useful to protect the bone marrow and other organs, including the kidney and lung, from toxic insult. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials for the potential treatment of chemotherapy-induced myelosuppression. Visit www.g1therapeutics.com for more information.


'/>"/>
SOURCE G1 Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics Reports Third Quarter 2013 Financial Results
2. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
3. Abide Therapeutics Appoints Dr. Gary ONeill as Vice President of Biology
4. Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013
5. Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure
6. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
7. ISSYS Inc. will showcase its Titan Wireless Implantable Hemodynamic Monitor and its clinical study summary at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference (Booth 1638) in San Francisco (October 29 to 31, 2013)
8. Aratana Therapeutics Adds to Commercial Leadership Team
9. Mirati Therapeutics Prices Public Offering Of Common Stock
10. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
11. Cell Therapeutics to Report Third Quarter Financial Results after Market on October 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):